Acute Myeloid Leukemia (AML) Therapeutics

World Market Report

MCP-6847

EXECUTIVE ENGAGEMENTS

POOL

5362
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

858
Interactions with Platform & by Email

PARTICIPANTS

161
Unique # Participated

VALIDATIONS

33
Responses Validated*

COMPANIES

112
Responses Validated*
* Login for a full stack data experience

DATE

OCT 2022

TABLES

90

PAGES

356

EDITION

18

PRICE

USD 5450

CODE

MCP-6847


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

RANK

(S/A/N/T)

%

VALIDATED RESEARCH *

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $1.1 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$476.9 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 12.6% over the analysis period 2020-2027. Cytarabine, one of the segments analyzed in the report, is projected to record a 15.1% CAGR and reach US$366.4 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Anthracycline Drugs segment is readjusted to a revised 13.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $177.4 Million, While China is Forecast to Grow at 14.9% CAGR
The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$177.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$97 Million by the year 2027 trailing a CAGR of 14.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 11.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.Tyrosine Kinase Inhibitors Segment to Record 10.5% CAGR
In the global Tyrosine Kinase Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 10.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$52.6 Million in the year 2020 will reach a projected size of US$103.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

SELECT PLAYERS

AbbVie Inc.; Actinium Pharmaceuticals, Inc.; Amgen Inc.; Astellas Pharma Inc.; Astex Pharmaceuticals, Inc. ; CTI BioPharma Corp.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo Company Limited; F. Hoffmann-La Roche AG; Janssen-Cilag Limited; Jazz Pharmaceuticals plc; MEI Pharma, Inc.; Merus N.V.; Novartis AG; Pfizer Inc.; Takeda Pharmaceutical Company Limited

SEGMENTS

» Chemotherapy Type (Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites, Other Chemotherapy Types)

GEOGRAPHIES

» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » Australia » India » South Korea » Rest of Asia-Pacific » Latin America » Middle East » Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
COVID-19 IMPACT AND THE LOOMING RECESSION
COVID-19’s Impact on Cancer Patients
Making the Cancer Patient Survive the Lethal Covid-19 Wave
Post-Covid-19 Complications to Affect Future Cancer Treatment
The Evolving Model of Care - Virtual/ Telemedicine Consultations
The Evolving Model of Care - Extending Care through Innovative Means
Pandemic Causes Delays in Procedures and Treatment
In-Office Cancer Patient Visits Decline amidst Pandemic
Vaccine Availability Comforts Cancer Patients
COVID-19 IMPACT ON ACUTE MYELOID LEUKEMIA THERAPEUTICS
Pandemic Caused Delays Impact AML Patients
Pandemic Related Issues Affect Oncology Research
Competition
Competitive Market Presence - Strong/Active/Niche/Trivial for 67 Players Worldwide in 2022 (E)
Acute Myeloid Leukemia (AML) Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E)
LEUKEMIA – A DISEASE OF THE BONE MARROW
A Prelude to Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia: Epidemiology
Acute Myeloid Leukemia (AML) Types
Etiology of AML
AML Symptoms
GLOBAL MARKET OUTLOOK AND PROSPECTS
Acute Myeloid Leukemia (AML) Therapeutics Market Primed for Massive Growth with Rising Patient Count & Promising Research Efforts
Drug Development Efforts Set Pace for Global Market
New Therapies Introduced in the Landscape
RECENT LAUNCHES IN THE AML MARKET
North America Maintains Leadership Position in Global Market
Chemotherapy: The Standard Mode of Treatment for AML Over the Years
Emerging Drug Therapies/Targeted Therapies for Acute Myeloid Leukemia to Drive the Market
FLT3 Inhibitors & Cytarabine: Bright Segments of Acute Myeloid Leukemia Therapeutics Market
Global FLT3 Inhibitors Market: Annual Sales in US$ Million for Years 2020 through 2027
EXISTING & POTENTIAL TREATMENT/THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA
Chemotherapy
AML Treatment
Stem Cell Transplant for Acute Myeloid Leukemia (AML)
Targeted Therapies Drive the Future of AML Market
ISOCITRATE DEHYDROGENASES (IDH)
BCL-2 Inhibitor
FLT3
Hedgehog (Hh)
Immunotherapy-Oriented Treatments
Neurotransmitter Receptors
Epigenetic Modulators
Organelle-Directed Strategies
New Formulations Using Existing Options
Antibody–Drug Conjugate Therapy for Acute Leukemia
Targeted Therapies Market for AML by Product Class: Market Size Estimates in USD Million for 2020
Targeted Therapies Market for AML (2020) by Leading Drugs: Market Share of Revenues
RECENT MARKET ACTIVITY
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
High Incidence and Prevalence Drive Market Growth
Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics
EXHIBIT 12: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
Life Expectancy for Select Countries in Number of Years: 2019
Advancements in Pharmacology & Molecular Biology to Promote AML Drug Development
Recent Drug Approvals
Rising Investments in AML Therapeutics R&D Augurs Well
Changing Face of Combination Therapies Improve Outcomes for treated Secondary AML
University of Texas’ Combination Therapy Study Shines Light at the end of Tunnel for Acute Myeloid Leukemia
Need for Better Treatments Entrenches Proteomics at Center of Acute Myeloid Leukemia Therapeutics R&D
Antibody-Oriented Protein Microarrays
AML - A Medical Challenge with High Relapse Rate
Therapeutic Landscape for Refractory/Relapsed Acute Myeloid Leukemia
Advances Related to FLT3 Inhibitors
Novel Combination Therapies for Relapsed or Refractory AML
Novel Therapies for Treatment of Pediatric Relapsed AML
Immunotherapy Research for AML
Monoclonal Antibody (Mylotarg) – A Promising Drug
Chemotherapy Complications to Hinder the AML Market Growth
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cytarabine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anthracycline Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-Metabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Chemotherapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
UNITED STATES
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
JAPAN
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
CHINA
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
EUROPE
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
FRANCE
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
GERMANY
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
UNITED KINGDOM
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
SPAIN
Spain Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
RUSSIA
Russia Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
AUSTRALIA
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
Australia Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
INDIA
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
India Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
India Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
SOUTH KOREA
South Korea Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
LATIN AMERICA
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
Latin America Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
MIDDLE EAST
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
Middle East Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027
AFRICA
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
Africa Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2012, 2021 & 2027

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com